{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Respiratory+Disease",
    "query": {
      "condition": "Severe Respiratory Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 936,
    "total_pages": 94,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Respiratory+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T17:18:18.740Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01110421",
      "title": "A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumonia, Bacterial",
        "Community-Acquired Infections",
        "Nosocomial Infection",
        "Pneumonia, Ventilator-Associated"
      ],
      "interventions": [
        {
          "name": "Cefepime placebo",
          "type": "DRUG"
        },
        {
          "name": "Cefepime",
          "type": "DRUG"
        },
        {
          "name": "Doripenem",
          "type": "DRUG"
        },
        {
          "name": "Doripenem placebo",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin/clavulanate potassium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Months to 18 Years"
      },
      "enrollment_count": 7,
      "start_date": "2010-12",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2014-07-15",
      "last_synced_at": "2026-09-27T17:18:18.740Z",
      "location_count": 4,
      "location_summary": "Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110421"
    },
    {
      "nct_id": "NCT03613558",
      "title": "Dex as Analgesic Adjuvant in OSA Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Obstructive Sleep Apnea"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-07",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2018-08-03",
      "last_synced_at": "2026-09-27T17:18:18.740Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03613558"
    },
    {
      "nct_id": "NCT04780685",
      "title": "A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "hMSC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Stemedica Cell Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-03-20",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-07-08",
      "last_synced_at": "2026-09-27T17:18:18.740Z",
      "location_count": 2,
      "location_summary": "Fullerton, California • Santa Monica, California",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04780685"
    },
    {
      "nct_id": "NCT02687204",
      "title": "Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Deep Venous Thrombosis",
        "Pulmonary Embolus"
      ],
      "interventions": [
        {
          "name": "Twice daily enoxaparin prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Real time dose adjustment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2016-03",
      "completion_date": "2017-12-06",
      "has_results": false,
      "last_update_posted_date": "2018-10-19",
      "last_synced_at": "2026-09-27T17:18:18.740Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02687204"
    },
    {
      "nct_id": "NCT02272634",
      "title": "A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "YPL-001 80 mg",
          "type": "DRUG"
        },
        {
          "name": "YPL-001 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yungjin Pharm. Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 61,
      "start_date": "2015-06-04",
      "completion_date": "2017-11-08",
      "has_results": true,
      "last_update_posted_date": "2023-07-14",
      "last_synced_at": "2026-09-27T17:18:18.740Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Winter Park, Florida • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02272634"
    },
    {
      "nct_id": "NCT04542993",
      "title": "Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "SARS-CoV Infection"
      ],
      "interventions": [
        {
          "name": "Zinc Picolinate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Resveratrol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Zinc Picolinate Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Resveratrol Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Swedish Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 45,
      "start_date": "2020-09-08",
      "completion_date": "2021-02-05",
      "has_results": false,
      "last_update_posted_date": "2022-07-29",
      "last_synced_at": "2026-09-27T17:18:18.740Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04542993"
    },
    {
      "nct_id": "NCT04725110",
      "title": "Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "SARS-CoV Infection",
        "ARDS",
        "ARDS, Human"
      ],
      "interventions": [
        {
          "name": "Instilled T3",
          "type": "DRUG"
        },
        {
          "name": "Placebo Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2026-01-15",
      "completion_date": "2031-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-09-27T17:18:18.740Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04725110"
    },
    {
      "nct_id": "NCT04545385",
      "title": "A Study to Test if TEV-48574 is Effective in Relieving Asthma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "TEV-48574",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2020-10-07",
      "completion_date": "2022-01-17",
      "has_results": true,
      "last_update_posted_date": "2023-03-13",
      "last_synced_at": "2026-09-27T17:18:18.740Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04545385"
    },
    {
      "nct_id": "NCT02587325",
      "title": "Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "nab-sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aadi Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-04-01",
      "completion_date": "2022-09-16",
      "has_results": true,
      "last_update_posted_date": "2024-11-25",
      "last_synced_at": "2026-09-27T17:18:18.740Z",
      "location_count": 6,
      "location_summary": "Tucson, Arizona • Torrance, California • Indianapolis, Indiana + 3 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02587325"
    },
    {
      "nct_id": "NCT00006368",
      "title": "Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Breast Cancer",
        "Gastrointestinal Carcinoid Tumor",
        "Islet Cell Tumor",
        "Lung Cancer",
        "Lymphoma",
        "Melanoma (Skin)",
        "Neoplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "yttrium Y 90-edotreotide",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "1998-01",
      "completion_date": "2003-11",
      "has_results": false,
      "last_update_posted_date": "2013-05-01",
      "last_synced_at": "2026-09-27T17:18:18.740Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006368"
    }
  ]
}